Dr Reddy’s | Business Upturn

Torrent Pharma, Dr. Reddy’s and Zydus Life benefit as generic Semaglutide market share rises to 33% within 10 days of launch

Markets Desk — Mon, 20 Apr 2026 04:46:07 +0000

The launch of generic Semaglutide in India has made an immediate and dramatic impact on the obesity and diabetes drug market, with CLSA’s latest healthcare channel check note revealing a rapid market share gain that has caught even optimistic analysts off-guard. According to CLSA, within just 10 days of the generic Semaglutide launch in March 2026, its market share jumped from 25% to 33% — a sharp 8 percentage point gain in less than a fortnight.

The beneficiaries have been clearly identified. CLSA’s note points to Torrent Pharmaceuticals, Dr. Reddy’s Laboratories and Zydus Lifesciences as the primary gainers from the increased market share, citing their well-established sales forces and strategic focus on diabetic and cardiovascular therapies as the key competitive advantages that have allowed them to capture the incremental share quickly. All three companies have strong existing relationships with endocrinologists and cardiologists — the two specialist communities driving the bulk of Semaglutide prescriptions — giving them a significant distribution and detailing edge over competitors entering this space.

The flip side of generic Semaglutide’s rise has been a dent in the market dominance of Eli Lilly’s Tirzepatide, sold under the brand name Mounjaro. CLSA’s channel checks show Mounjaro’s market share declining from 61% in February 2026 to 56% in March 2026, a five percentage point erosion in a single month. While Tirzepatide continues to lead the market by a wide margin, the trajectory is clear — generic Semaglutide is eating into its share at a pace that could accelerate materially as prescription-led demand builds.

CLSA flagged an important nuance for investors to keep in mind, however. The brokerage noted that much of the initial increase in Semaglutide sales has been driven by an inventory push to stockists rather than end-patient prescription-driven demand. This means the full organic demand picture is not yet visible in the data. CLSA believes prescription-led sales should pick up meaningfully in the coming months, which would represent a second, more durable wave of volume growth for Torrent, Dr. Reddy’s and Zydus — making the current channel fill a floor rather than a ceiling for future performance.

The Semaglutide opportunity in India is part of a broader global narrative around GLP-1 receptor agonists, a class of drugs that has reshaped the treatment landscape for type 2 diabetes and obesity. With generics now entering the Indian market at accessible price points, the addressable patient population expands considerably — and the companies best positioned to capture this expansion are those with the strongest metabolic disease franchises, physician relationships and manufacturing scale.

Top losers among Nifty 50 stocks in midday trades today, Feb 10: Shriram Finance, Bajaj Finance, Dr. Reddy’s, SBI Life and more

Aman Shukla — Tue, 10 Feb 2026 06:44:11 +0000

Indian equity benchmarks were trading modestly higher in midday deals on February 10, with the NIFTY up 0.35% at 25,958.85 and the Sensex gaining 0.38% to 84,381.11. Despite the broader market strength, several heavyweight Nifty 50 stocks were trading in the red, weighing on sector-specific sentiment.

Shriram Finance emerged as the top loser among Nifty 50 stocks, declining 1.8% to ₹1,043.10 in midday trade.

Bajaj Finance was down 1.7% at ₹966.30, making it one of the biggest drags within the index during the session. Pharmaceutical major Dr. Reddy’s Laboratories slipped 1.5% to ₹1,256.10.

SBI Life Insurance traded 1.0% lower at ₹2,004.20. Paint major Asian Paints declined 0.9% to ₹2,396.80. Tata Consumer Products slipped 0.8% to ₹1,157.60, while IT major HCL Technologies traded 0.7% lower at ₹1,590.30.

Telecom heavyweight Bharti Airtel was also down 0.7% at ₹2,024.40. Adani Enterprises slipped 0.6% to ₹2,236.70, while FMCG major ITC rounded out the list, trading 0.4% lower at ₹321.60 in midday deals.

Overall, while headline indices remained in positive territory, profit-taking in select large-cap stocks led to mild underperformance among these Nifty 50 constituents during the midday session on February 10 (IST).

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Top stocks for trade today, Jan 22: Eternal, Dr Reddy’s, Shriram Finance, Bank of India, Nestlé India and more

Aman Shukla — Thu, 22 Jan 2026 03:27:39 +0000

Indian equity markets are expected to witness stock-specific movements on Thursday, January 22, as investors react to a busy mix of quarterly earnings announcements, management changes, regulatory approvals and policy-related updates. With the broader indices remaining range-bound in recent sessions, company-specific triggers are likely to dominate trading sentiment.

Stocks to Watch Today – January 22

Eternal: Q3 results came in above estimates. Deepinder Goyal to step down as CEO; Albinder Dhindsa to take over.
Dr Reddy’s Laboratories: EBITDA and margins reported above estimates. Company expects semaglutide launch in Canada between January and March 2026.
Shriram Finance: Fitch placed the company’s ‘BB+’ ratings on Rating Watch Positive.
Bank of India: Loan growth reported at 13.6%, in line with guidance of 13–14%. Net interest income rose 6.4% year-on-year.
Nestlé India: Supreme Court dismissed the Income Tax Department’s appeal related to a ₹101 crore tax claim.
JSW Steel: Received Competition Commission of India approval for the Bhushan Power and Steel deal with JFE Steel Corporation, Japan.
Oracle Financial Services Software: Revenue increased 10% quarter-on-quarter. Returned to double-digit revenue growth after four quarters.
Waaree Energies: EBITDA rose 37.2% quarter-on-quarter. Margin improved to 25.5% from 23.2%.
Canara HSBC Life Insurance: Total APE increased 37.4%. Value of new business rose 66% year-on-year.
Bajaj Consumer Care: Revenue grew 30.5% year-on-year. Net profit increased 83.4% year-on-year.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Nifty 50 top losers today, January 1: ITC, Dr. Reddy’s, Bajaj Finance, Tata Consumer Products, ONGC, Cipla and more

Aman Shukla — Thu, 01 Jan 2026 10:22:51 +0000

Indian equity benchmarks ended the first trading session of 2026 on a mixed note as markets witnessed intraday volatility. The Sensex slipped 32 points, or 0.04 percent, to close at 85,188.60, while the Nifty 50 edged higher by 16.95 points, or 0.06 percent, settling at 26,146.55. Despite the marginal overall movement, several heavyweight stocks ended the session in the red. Here are the top losers from the Nifty 50 index (as per Trendline).

Top Nifty 50 Losers

ITC was the top loser on the Nifty 50, closing at ₹363.90, down 9.7%.
Dr. Reddy’s Laboratories ended at ₹1,253.40, registering a 1.4% decline.
Bajaj Finance closed at ₹973.10, down 1.4%.
Tata Consumer Products finished the session at ₹1,176.90, lower by 1.3%.
Oil and Natural Gas Corporation closed at ₹237.90, declining 1.0%.
Cipla ended at ₹1,500.90, down 0.7%.
Asian Paints settled at ₹2,752.00, slipping 0.6%.
Bharat Electronics closed at ₹397.70, lower by 0.5%.
ICICI Bank ended the day at ₹1,338.00, down 0.4%.
Bajaj Finserv closed at ₹2,037.00, marginally lower by 0.1%.

Nifty 50 top losers today, December 24: IndiGo, Dr. Reddy’s, Wipro, Adani Enterprises, HDFC Life, Tata Motors PV and more

Aman Shukla — Wed, 24 Dec 2025 10:15:52 +0000

Indian equity benchmarks ended marginally lower in a highly volatile session on December 24, with selling pressure visible across several heavyweight stocks. The Sensex slipped 116.14 points, or 0.14 percent, to close at 85,408.70, while the Nifty 50 declined 35.05 points, or 0.13 percent, to settle at 26,142.10. Here are the top gainers from the Nifty 50 index (as per Trendline).

Top Nifty 50 Losers

IndiGo closed at ₹5,081.5, down 1.5%.
Dr. Reddy’s Laboratories ended at ₹1,267.1, down 1.3%.
Wipro closed at ₹268.1, lower by 1.2%.
Adani Enterprises settled at ₹2,222.7, down 1.2%.
HDFC Life Insurance closed at ₹755.4, down 1.1%.
Tata Motors Passenger Vehicles ended at ₹359.2, lower by 1.1%.
Sun Pharmaceutical Industries closed at ₹1,737.0, down 1.1%.
Hindustan Unilever ended at ₹2,282.2, lower by 0.9%.
Reliance Industries closed at ₹1,558.2, down 0.8%.
Asian Paints settled at ₹2,785.5, lower by 0.8%.

Nifty 50 top losers today, October 14: Tata Motors, Dr. Reddy’s, Bharat Electronics, Bajaj Finance, TCS, Tata Steel and more

Aman Shukla — Tue, 14 Oct 2025 10:12:18 +0000

Indian equity markets closed lower on October 14, with the Nifty ending below 25,200 amid broad-based selling. The Sensex fell 297.07 points, or 0.36%, to settle at 82,029.98, while the Nifty dropped 81.85 points, or 0.32%, closing at 25,145.50. Amid the broad market weakness, several Nifty 50 stocks saw notable declines. Here’s a look at Nifty top losers (According to Trendline).

Nifty 50 top losers

Tata Motors, down 40.2%, closing at ₹395.5
Dr. Reddy’s, down 2.0%, closing at ₹1,237.3
Bharat Electronics, down 1.7%, closing at ₹402.4
Bajaj Finance, down 1.7%, closing at ₹1,019.2
Tata Consultancy Services, down 1.6%, closing at ₹2,960.3
Tata Steel, down 1.5%, closing at ₹170.5
NTPC, down 1.4%, closing at ₹336.9
Trent, down 1.4%, closing at ₹4,617.2
Hindalco Industries, down 1.3%, closing at ₹760.1
JSW Steel, down 1.2%, closing at ₹1,147.0

Nifty 50 top losers today, September 15: Cipla, Asian Paints, Mahindra & Mahindra, Shriram Finance, Dr. Reddy’s and more

Aman Shukla — Mon, 15 Sep 2025 10:11:58 +0000

Indian equity markets ended on a subdued note on September 15, with benchmark indices slipping in a rangebound session. The Sensex fell 118.96 points, or 0.15 percent, to 81,785.74, while the Nifty closed 44.80 points lower, or 0.18 percent, at 25,069.20. Here’s a look at the biggest losers of the day, according to Trendline:

Nifty 50 top losers on September 12

Cipla closed 1.8% lower at ₹1,547.0
Asian Paints closed 1.7% lower at ₹2,502.6
Mahindra & Mahindra closed 1.7% lower at ₹3,530.3
Shriram Finance closed 1.5% lower at ₹623.7
Dr. Reddy’s Laboratories closed 1.2% lower at ₹1,301.0
Infosys closed 1.1% lower at ₹1,508.4
Titan Company closed 1.1% lower at ₹3,531.9
Eicher Motors closed 1.1% lower at ₹6,799.0
Sun Pharmaceutical closed 0.9% lower at ₹1,602.0
Tata Consultancy Services closed 0.7% lower at ₹3,111.9

Nifty top gainers today, July 4: Bajaj Finance, Dr. Reddy’s, Infosys, Hindustan Unilever, ICICI Bank and more

Aman Shukla — Fri, 04 Jul 2025 10:07:11 +0000

Indian equity benchmarks ended the July 4 trading session on a positive note, despite intraday volatility. The BSE Sensex gained 193.42 points, or 0.23%, to close at 83,432.89. Meanwhile, the NSE Nifty 50 rose by 55.70 points, or 0.22%, ending at 25,461.00.

Several heavyweight Nifty 50 stocks stood out by posting decent gains, led by Bajaj Finance, Dr. Reddy’s and Infosys. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day.

Nifty 50 Top Gainers on July 4

Bajaj Finance closed at ₹926.00, up by 1.7%.
Dr. Reddy’s Laboratories ended at ₹1,310.00, gaining 1.5%.
Infosys settled at ₹1,639.70, rising by 1.3%.
Hindustan Unilever closed at ₹2,341.30, up 1.2%.
ICICI Bank ended the session at ₹1,443.00, also up 1.2%.
Wipro rose 0.9% to close at ₹269.50.
UltraTech Cement finished at ₹12,505.00, also gaining 0.9%.
HCL Technologies closed at ₹1,725.90, higher by 0.8%.
Reliance Industries ended at ₹1,528.10, up 0.7%.
Hero MotoCorp closed at ₹4,337.80, advancing 0.6%.

Nifty 50 top gainers today, July 3: Dr. Reddy’s, Apollo Hospitals, Hero MotoCorp, ONGC and more

Aman Shukla — Thu, 03 Jul 2025 10:11:00 +0000

Indian equity markets closed in the red on Wednesday, July 3, after a choppy trading session. The benchmark indices slipped slightly, with the Sensex falling 170 points to settle at 83,239.47, while the Nifty 50 ended 48 points lower at 25,405.30.

Despite the weak broader market sentiment, several heavyweight Nifty 50 stocks stood out by posting decent gains, led by Dr. Reddy’s Laboratories, Apollo Hospitals, and Hero MotoCorp. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day.

Nifty 50 Top Gainers on July 3

Dr. Reddy’s Laboratories closed at ₹1,295.00, up 1.9%.
Apollo Hospitals Enterprises ended at ₹7,572.50, rising 1.8%.
Hero MotoCorp closed at ₹4,310.60, up 1.6%.
Oil and Natural Gas Corporation finished at ₹244.00, gaining 1.2%.
Maruti Suzuki India ended at ₹12,750.00, up 1.0%.
Cipla closed at ₹1,507.50, up 0.7%.
Infosys ended at ₹1,618.70, higher by 0.5%.
IndusInd Bank closed at ₹862.00, also up 0.5%.
Asian Paints finished at ₹2,430.50, up 0.5%.
Bajaj Auto ended the session at ₹8,392.50, with a gain of 0.4%.

Nifty 50 top losers this week (June 28): ONGC, Dr. Reddy’s, Tech Mahindra, Maruti Suzuki India and more

Aman Shukla — Sat, 28 Jun 2025 04:02:58 +0000

Indian stock markets wrapped up the week on a strong note, with benchmark indices extending their gains for the second consecutive week. Both the Sensex and Nifty 50 advanced over 2%, supported by broad-based buying across sectors. A major milestone came from the Nifty Bank index, which closed above the 57,400 mark for the first time.

However, not all stocks participated in the rally. Several major stocks underperformed this week, with ONGC, Dr. Reddy’s and Tech Mahindra leading the losses. Let’s take a closer look at the top 10 losers of the Nifty 50 this week, according to Trendlyne.

Nifty 50 Top Losers This Week

Oil and Natural Gas Corporation (ONGC) closed at ₹242.8, down 3.6% for the week.
Dr. Reddy’s Laboratories ended the week at ₹1301.0, registering a 1.8% drop.
Tech Mahindra declined 1.3%, closing at ₹1674.4.
Maruti Suzuki India slipped 1.2% during the week to ₹12,642.0.
HCL Technologies ended the week lower by 1.0%, closing at ₹1723.3.
Infosys closed at ₹1608.0, posting a 0.9% weekly decline.
Wipro slipped 0.6% this week to close at ₹265.1.
Hero MotoCorp saw a minor weekly dip of 0.4%, ending at ₹4320.3.

Nifty 50 top losers today, June 27: Tata Consumer Products, Dr. Reddy’s, Wipro, SBI Life and more

Aman Shukla — Fri, 27 Jun 2025 10:13:21 +0000

Indian stock markets ended on a high note on June 27, with the Sensex rising 303 points to 84,058.90 and the Nifty gaining 88.80 points to close at 25,637.80.

However, not all stocks shared in the rally. A few prominent Nifty 50 companies ended the session in the red. Among the biggest losers of the day were well-known names like Tata Consumer Products, Dr. Reddy’s and Wipro. Let’s take a closer look at the top losers of the Nifty 50, according to Trendlyne.

Nifty 50 top losers on June 27

Tata Consumer Products was the top loser, falling 2.1% to close at ₹1,121.
Dr. Reddy’s Laboratories declined 1.4%, ending the day at ₹1,302.5.
Wipro slipped 1.2% and closed at ₹265.4.
SBI Life Insurance dropped 1% to ₹1,843.
Bajaj Finserv closed 0.9% lower at ₹2,036.
Axis Bank also declined 0.9%, settling at ₹1,223.
Eternal lost 0.8% and ended at ₹263.
Bajaj Finance was down 0.8%, closing at ₹944.
Trent fell 0.8% and finished at ₹6,059.
Grasim ended the day 0.7% lower at ₹2,863.3.

Nifty 50 top losers this week (June 21): Tata Motors, Adani Ports, Bajaj Finance, Dr. Reddy’s, Adani Enterprises and more

Aman Shukla — Sat, 21 Jun 2025 03:56:37 +0000

Indian stock markets ended the week on a positive note, with benchmark indices posting solid gains. Both the Nifty 50 and Sensex rose over 1.5% for the week, recovering losses from the previous week.

Several major stocks underperformed this week, with Tata Motors, Adani Ports and Bajaj Finance leading the losses. Let’s take a closer look at the top 10 losers of the Nifty 50 this week, according to Trendlyne.

Nifty 50 Top Losers This Week

Tata Motors closed at ₹676.2, down 5.0% for the week despite a modest daily gain of 0.6%.
Adani Ports and Special Economic Zone ended at ₹1349.3, falling 4.0% over the week.
Bajaj Finance settled at ₹905.0, recording a weekly loss of 3.0%.
Dr. Reddy’s Laboratories closed at ₹1325.3, down 2.7% this week.
Adani Enterprises ended the week at ₹2448.4, registering a 2.4% decline.
Sun Pharmaceutical Industries slipped 1.3% to finish at ₹1665.1.
Bajaj Finserv closed at ₹1986.2, falling 1.2% during the week.
Bajaj Auto declined 1.1%, ending the week at ₹8371.0.
Nestle India recorded a 0.7% drop to settle at ₹2360.4.
Hindustan Unilever closed the week at ₹2306.2, down 0.6%.

Nifty 50 top losers today, June 20: Bajaj Auto, Hero MotoCorp, Dr. Reddy’s, Maruti Suzuki and more

Aman Shukla — Fri, 20 Jun 2025 10:14:06 +0000

Indian stock markets ended the trading session on a high note on June 20, with benchmark indices surging to high levels. The Nifty 50 crossed the 25,000 mark, closing at 25,112.40, up by 319.15 points (1.29%). The BSE Sensex also witnessed a strong rally, rising 1,046.30 points (1.29%) to settle at 82,408.17.

Despite the market’s overall bullish trend, several heavyweight stocks saw significant declines during the session. Among the biggest losers of the day were well-known names like Bajaj Auto, Hero MotoCorp and Dr. Reddy’s. Let’s take a closer look at the top losers of the Nifty 50, according to Trendlyne.

Nifty 50 top losers on June 20

Bajaj Auto was the top loser, closing 1.8% lower at ₹8,345.
Hero MotoCorp ended the session down by 1.2%, settling at ₹4,331.1.
Dr. Reddy’s declined 0.3% to close at ₹1,322.8.
Maruti Suzuki slipped 0.2% and ended at ₹12,787.
ONGC registered a marginal drop of 0.1%, closing at ₹251.2.
Axis Bank also fell 0.1% to finish at ₹1,216.1.
Infosys ended flat, closing unchanged at ₹1,618.

Nifty 50 top losers today, June 17: Adani Enterprises, Dr. Reddy’s, Tata Motors, Sun Pharma lead declines

Aman Shukla — Tue, 17 Jun 2025 10:11:05 +0000

Indian equity benchmarks closed lower on Tuesday, June 17, 2025, as cautious market sentiment weighed on investor confidence. The BSE Sensex dropped 212.85 points (0.26%) to settle at 81,583.30, while the NSE Nifty 50 declined 93.10 points (0.37%), closing at 24,853.40.

Several major Nifty 50 stocks saw pressure, dragging the indices lower. Among the biggest losers of the day were well-known names like Adani Enterprises, Eternal and Dr. Reddy’s Laboratories. Let’s take a closer look at the top losers of the Nifty 50, according to Trendlyne.

Nifty 50 top losers on June 17

Adani Enterprises closed at ₹2,485.20, down 2.3%.
Eternal ended at ₹247.00, falling 2.1%.
Dr. Reddy’s Laboratories settled at ₹1,319.90, down 2.0%.
Tata Motors closed at ₹673.00, down 2.0%.
Sun Pharmaceutical Industries ended at ₹1,653.10, slipping 1.9%.
Oil and Natural Gas Corporation (ONGC) closed at ₹252.00, down 1.9%.
Shriram Finance finished at ₹663.90, losing 1.8%.
Cipla closed at ₹1,503.90, down 1.5%.
Bajaj Finance ended at ₹924.00, down 1.5%.
Jio Financial Services settled at ₹289.80, falling 1.5%.

Nifty 50 top gainers today, June 12: Apollo Hospitals, Asian Paints, Bajaj Finserv, Dr. Reddy’s and more

Aman Shukla — Thu, 12 Jun 2025 10:12:53 +0000

Indian equity markets closed in the red on June 12, as both benchmark indices recorded notable declines. The Sensex fell 823.16 points or 1.00% to close at 81,691.98, while the Nifty 50 dropped 253.20 points or 1.01%, ending the session at 24,888.20.

Despite the broader weakness, a few Nifty 50 constituents managed to register gains. According to data from Trendlyne, here are the top gainers of the day:

Nifty 50 Top Gainers on June 12

Apollo Hospitals Enterprises closed at ₹6994.00, up 1.0%.
Asian Paints ended at ₹2225.00, gaining 0.7%.
Bajaj Finserv closed at ₹2022.10, rising 0.5%.
Dr. Reddy’s Laboratories settled at ₹1356.30, up 0.4%.
Tech Mahindra finished at ₹1643.60, also gaining 0.4%.
Wipro ended the day at ₹259.10, with a marginal increase of 0.1%.
Oil and Natural Gas Corporation closed flat at ₹247.40.

Nifty 50 top gainers this week (June 7): Eternal, Shriram Finance, Dr. Reddy’s, Mahindra & Mahindra and more

Aman Shukla — Sat, 07 Jun 2025 04:27:52 +0000

Indian stock markets closed the week on a positive note, rebounding after two straight weeks of losses. A surprise policy pivot by the Reserve Bank of India (RBI) boosted investor sentiment, especially in rate-sensitive sectors such as financials and real estate.

The NSE Nifty 50 index climbed 1% on Friday to close at 25,003, while the BSE Sensex surged 747 points on Friday to end at 82,189. The Nifty Bank index also gained traction, rising nearly 2% during the week to finish at 56,578.

Several Nifty 50 stocks posted impressive weekly gains, with Eternal, Shriram Finance and Dr. Reddy’s leading the charge. Let’s take a look at the top gainers of Nifty 50 this week, as per Trendlyne data.

Top Stock Gainers This Week (Ending June 7, 2025)

Eternal gained 9.9% this week, closing at ₹261.9.
Shriram Finance rose 7.7%, ending the week at ₹688.3.
Dr. Reddy’s Laboratories increased 5.6%, with a closing price of ₹1320.9.
Mahindra & Mahindra advanced 4.4%, closing at ₹3106.5.
Adani Ports & Special Economic Zone was up 2.7%, settling at ₹1471.7.
Hindalco Industries added 2.6%, finishing the week at ₹650.2.
Cipla also gained 2.6%, with a closing value of ₹1504.2.
Jio Financial Services climbed 2.6%, ending at ₹294.0.
Trent moved up 2.4%, closing the week at ₹5777.0.
Power Grid Corporation edged higher by 2.1%, with a closing price of ₹295.8.

Nifty 50 top gainers today, June 5: Eternal, Trent, Dr. Reddy’s, Power Grid, ICICI Bank and more

Aman Shukla — Thu, 05 Jun 2025 10:10:13 +0000

Indian equity markets continued their upward momentum on June 5, with the Nifty 50 closing above the 24,750 level. The Sensex gained 443.79 points, or 0.55%, to close at 81,442.04, while the Nifty 50 rose by 130.70 points, or 0.53%, ending the day at 24,750.90.

Among the Nifty 50 stocks, several companies recorded significant gains, led by Eternal, Trent and Dr. Reddy’s. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day.

Nifty 50 Top Gainers on June 5

Eternal gained 4.4% and closed at ₹256.6.
Trent rose 3.2% to close at ₹5680.0.
Dr. Reddy’s Laboratories increased by 3.1%, closing at ₹1290.1.
Power Grid Corporation went up 2.0% to close at ₹294.3.
ICICI Bank added 1.7%, ending the day at ₹1454.8.
Shriram Finance rose 1.6%, closing at ₹651.5.
UltraTech Cement advanced 1.3% to ₹11180.0.
Reliance Industries gained 1.3%, closing at ₹1442.4.
Cipla increased by 1.2%, with a close of ₹1490.0.
Adani Ports & Special Economic Zone rose 1.2% to ₹1453.0.

Dr. Reddy’s shares surge 4% after company partners with Alvotech to develop and commercialize Biosimilar to Keytruda

Aman Shukla — Thu, 05 Jun 2025 03:59:02 +0000

Shares of Dr. Reddy’s Laboratories rose 4% in morning trade after the company announced a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilars. The two companies will co-develop and manufacture a biosimilar version of Keytruda® (pembrolizumab), a blockbuster immunotherapy drug used to treat various cancers.

Keytruda® generated global sales of US$29.5 billion in 2024, highlighting the significant market potential for its biosimilar version. Through this partnership, Dr. Reddy’s and Alvotech aim to accelerate development timelines and expand access to affordable cancer treatments across international markets.

As part of the agreement, both firms will jointly invest in R&D, manufacturing, and regulatory processes. Each partner retains global commercialization rights, with certain market exceptions, allowing for broad market reach while optimizing operational efficiency.

Dr. Reddy’s Laboratories shares opened at ₹1,264.20 and at the time of writing, surged to an intraday high of ₹1,303.40, matching the day’s low at the opening price. The stock is trading near its 52-week high of ₹1,421.49, significantly above its 52-week low of ₹1,020.00.

Dr. Reddy’s and Alvotech partner to develop and commercialize Biosimilar to Keytruda

Aman Shukla — Thu, 05 Jun 2025 03:11:26 +0000

Dr. Reddy’s Laboratories Ltd., a leading Indian pharmaceutical company, has entered into a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilar medicines. The partnership aims to co-develop, manufacture, and commercialize a biosimilar version of Keytruda® (pembrolizumab), a groundbreaking cancer treatment used for multiple cancer types worldwide.

Keytruda® is a highly successful immunotherapy drug, with global sales reaching an impressive US$29.5 billion in 2024. By combining their expertise, Dr. Reddy’s and Alvotech plan to accelerate the biosimilar’s development timeline and expand its availability across international markets.

Under the agreement, both companies will share development costs and responsibilities, ensuring efficient manufacturing and distribution. Each partner retains the right to commercialize the biosimilar globally, with certain exceptions, maximizing reach and impact.

“We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy’s. This agreement demonstrates Alvotech’s ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide,” said Róbert Wessman, chairman and CEO of Alvotech.

Dr. Reddy’s Laboratories shares surge 3% as Nomura reaffirms Buy’ rating, raising target price to Rs 1,575

Aman Shukla — Mon, 12 May 2025 05:49:29 +0000

Dr. Reddy’s Laboratories (DRL) saw its stock price jump by 3% after Nomura upgraded its outlook, reaffirming a ‘Buy’ rating and raising the target price to ₹1,575. This upgrade follows a robust Q4 performance, which exceeded market expectations, and a positive forecast for FY26.

For Q4, DRL reported a net profit of ₹1,587.3 crore, marking a 21.4% year-on-year growth and surpassing estimates by over 30%. The company’s revenue stood at ₹8,506 crore, while EBITDA margins improved to 29.1%, all ahead of analysts’ predictions. Notably, DRL’s businesses in North America, Europe, and Russia delivered exceptional results, contributing to a 12% EBITDA beat and a 33% profit-after-tax (PAT) beat.

Looking ahead, DRL has guided for double-digit revenue growth and an EBITDA margin of 25% for FY26. The company plans to drive these gains through strategic launches, portfolio expansion, and scaling in key markets. Nomura views these factors as setting up DRL for continued outperformance, supported by a solid product pipeline and strong execution.

Dr. Reddy’s Laboratories opened at ₹1,155.90, with the day’s high reaching ₹1,204.00 and a low of ₹1,143.90. The stock has been fluctuating within the 52-week range of ₹1,020.00 to ₹1,421.49.

Nifty 50 top gainers today, April 24: IndusInd Bank, UltraTech Cement, Grasim Industries, Dr. Reddy’s and more

Aman Shukla — Thu, 24 Apr 2025 10:06:20 +0000

Indian equity markets ended lower on April 24, with both key indices, the Sensex and Nifty 50, closing in the red. The Sensex dropped 315.06 points, or 0.39%, settling at 79,801.43, while the Nifty 50 declined by 82.25 points, or 0.34%, to close at 24,246.70.

Despite the broader market weakness, several Nifty 50 stocks posted strong gains, led by IndusInd Bank, UltraTech Cement, and Grasim Industries. Below is a detailed look at the top gainers of Nifty 50 (as per Trendline) for the day.

Nifty 50 Top Gainers on April 24

IndusInd Bank closed at ₹819.4, up by 3.2%.
UltraTech Cement ended at ₹12,175.0, marking a 1.9% increase.
Grasim Industries recorded a 1.7% rise, closing at ₹2,730.5.
Dr. Reddy’s Laboratories closed at ₹1,204.9, up by 1.6%.
Cipla saw a 1.3% increase, ending the session at ₹1,554.0.
Tata Motors gained 1.3%, closing at ₹668.4.
Sun Pharmaceutical ended at ₹1,806.9, up by 1.0%.
Tata Consumer Products closed at ₹1,160.9 with a 0.9% gain.
Titan Company rose by 0.8%, closing at ₹3,382.6.
Hero MotoCorp closed at ₹3,962.9, posting a 0.6% increase.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Dr Reddy’s shares fall 4% as Trump reiterates tariffs on pharmaceuticals ‘soon’

Aman Shukla — Wed, 09 Apr 2025 03:50:20 +0000

Dr Reddy’s Laboratories saw its stock decline by 4% after U.S. President Donald Trump signaled plans to impose tariffs on pharmaceutical imports. Speaking at a National Republican Congressional Committee event, Trump stated, “We’re gonna tariff our pharmaceuticals,” raising concerns among investors about potential duty hikes on drug imports.

While no specific measures have been announced yet, the remarks come shortly after the U.S. imposed a 104% tariff on select Chinese goods. Indian pharmaceutical companies, including Dr Reddy’s, are key exporters of generic drugs to the U.S., making them particularly sensitive to any potential tariff changes.

Analysts at CLSA noted that under a hypothetical 30% tariff scenario, Indian pharma companies could face earnings declines ranging from 24% to 45%. However, the firm also highlighted that the probability of such steep tariffs remains low due to Indian generics’ critical role in the U.S. healthcare system.

Indian drugmakers reportedly account for around 46% of generic savings in the U.S., which may deter aggressive tariff actions due to concerns around healthcare affordability and supply stability.

Dr. Reddy’s shares opened at ₹1,094.50, hitting a high of ₹1,094.55 and a low of ₹1,061.65 today. The stock remains volatile, trading closer to its 52-week low of ₹1,020.00 than its high of ₹1,421.49.

Dr Reddys shares rally today after Nuvama upgrades stock to ‘Buy’

Aditya Bhagchandani — Wed, 08 Jan 2025 04:09:45 +0000

Shares of Dr. Reddy’s Laboratories Limited surged by 2.88% to ₹1,390.50 in early trading today after Nuvama Research upgraded the stock to a ‘Buy’ from ‘Reduce,’ citing proactive measures by the company to mitigate risks associated with the upcoming Revlimid patent expiry in 2026.

Key Insights from Nuvama’s Report:

Revlimid Dependency: The patent expiry of Revlimid, which contributes approximately 40% to Dr. Reddy’s FY24 EBITDA, poses a substantial risk to earnings growth.
Proactive Mitigation: Management has outlined strategies to offset the revenue and EBITDA losses through key asset launches, including:
- Semaglutide in Canada
- Abatacept biosimilar in the US
Mitigation Impact: Nuvama estimates that Dr. Reddy’s proactive measures will cover about 80% of the anticipated EBITDA impact.
Valuation: The stock has been valued at 24x FY27E EPS, yielding a target price of ₹1,553, representing significant upside potential.
Risks: Potential delays in product approvals could pose challenges.

Dr. Reddy’s Laboratories Share Price history

Day	Open	Close	Change %
Tue, Jan 7 2025	₹1,352.00	₹1,351.55	+0.09%
Mon, Jan 6 2025	₹1,360.40	₹1,350.35	-0.17%
Fri, Jan 3 2025	₹1,375.05	₹1,352.65	-1.63%
Thu, Jan 2 2025	₹1,371.45	₹1,375.05	+0.44%
Wed, Jan 1 2025	₹1,388.45	₹1,369.00	-1.40%
Tue, Dec 31 2024	₹1,370.30	₹1,388.50	+0.84%
Mon, Dec 30 2024	₹1,389.60	₹1,376.90	-0.90%
Fri, Dec 27 2024	₹1,363.05	₹1,389.45	+2.53%

UBS initiates Sell call on Zydus, Dr Reddy’s, Aurobindo Pharma, Lupin

Markets Desk — Fri, 27 Sep 2024 02:12:17 +0000

UBS has initiated sell ratings on key Indian pharmaceutical stocks including Zydus, Dr. Reddy’s, Aurobindo, and Lupin, citing overestimated core margins and slow growth in their primary markets of India and the US. The brokerage believes the street is overly optimistic about the performance of these companies, which face challenges in achieving sustainable growth despite healthy balance sheets.

Key downgrades and price targets:

Zydus Life Sciences (Target Price: Rs 850) and Dr. Reddy’s Laboratories (Target Price: Rs 5700): UBS highlights that the market is overestimating core margins for both companies, leading to the sell rating.
Aurobindo Pharma (Target Price: Rs 1333): UBS has flagged high valuations despite low growth and a low return on capital employed (RoCE).
Lupin (Target Price: Rs 2250): The brokerage noted that the stock is already pricing in one-off benefits expected in FY25 and FY26, which may not be sustainable over the long term.

UBS pointed out that the slowdown in growth in India and the US — two markets that account for 70-80% of sector profits — is under-appreciated by the street. This slowdown is expected to result in lower growth across the sector. Although balance sheets remain healthy enough to allow for investment in new growth drivers, UBS suggests that growth normalization may take longer than anticipated.

Preferred picks: Sun Pharma and Cipla UBS, however, remains bullish on Sun Pharma and Cipla, issuing buy ratings on both stocks:

Sun Pharma (Target Price: Rs 2450): UBS expects Sun Pharma’s patented molecules to see revenues double over the next four years, accompanied by a 650 basis point margin expansion. This is expected to drive an earnings per share (EPS) compound annual growth rate (CAGR) of 19%.
Cipla (Target Price: Rs 2060): UBS likes Cipla’s potential upside in the US market from its injectable and respiratory portfolios, which, according to the brokerage, has not yet been fully factored in by the market.

Dr. Reddy’s refutes Congress allegations over engagement with Dhaval Buch’s Agora Advisory

Markets Desk — Tue, 10 Sep 2024 12:21:19 +0000

Dr. Reddy’s Laboratories has issued a statement addressing recent allegations made by the Congress party regarding the company’s engagement with Agora Advisory Private Limited. These allegations suggest potential conflicts of interest during the tenure of Madhabi Puri Buch as a whole-time director at the Securities and Exchange Board of India (SEBI).

Dr. Reddy’s clarified that it engaged Agora Advisory for a limited period from October 2020 to April 2021, specifically for leadership coaching services provided by Mr. Dhaval Buch. The total remuneration for these services amounted to Rs. 6,58,000 (six lakh, fifty-eight thousand rupees only).

The company emphasized its routine practice of engaging external coaches to facilitate significant role transitions for its leaders. “Mr. Dhaval Buch’s extensive experience with Unilever, both in India and globally, made him well-suited to coach the identified leader within our company. The remuneration paid to Mr. Buch was consistent with that of other coaches,” the statement read.

Dr. Reddy’s further asserted that the coaching assignment concluded well before Madhabi Puri Buch’s term as SEBI Chairperson. The company categorically denied any implications of preferential treatment by SEBI, labeling such suggestions as “baseless and malafide.”

In response to the broader allegations from the Congress party, which named several prominent companies including Mahindra and Mahindra, ICICI, Pidilite, Sembcorp, and Visu Leasing and Finance, Dr. Reddy’s reaffirmed its commitment to operating in full compliance with all applicable laws and regulations.

Dr Reddy’s signs non-exclusive patent licensing agreement with Takeda Pharma for Vonoprazan tablets in India

Markets Desk — Thu, 18 Jul 2024 12:26:35 +0000

Dr. Reddy’s today announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Dr. Reddy’s will market Vonoprazan tablets under its own trademark VONO ™ to be available in two strengths, 10mg and 20mg.

Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), are very common in India. A pan-Indian cross-sectional survey of clinicians showed APD prevalence to be in the range of 37-39%. It is more common in the 18-59 age group, with heart burn and epigastric pain as common symptoms’.

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, said, “For over three decades, patients and healthcare professionals have trusted our products in the gastrointestinal segment including well-known brands such as Omez®, Razo™ and others. Leveraging our expertise in this therapy area, we are pleased to make the first-in-class drug Vonoprazan (Vono ™) available to patients in India. The non-exclusive patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through strategic collaborations to meet unmet needs and enhance standard of care.”

Sensex gains more than 200 Points, while the Nifty trades over 17,200

Aryan Jakhar — Mon, 01 Aug 2022 04:32:33 +0000

The benchmarks for Indian equities opened higher on Monday, continuing their fourth straight session of gains.

Trends on the Singapore Exchange’s Nifty Futures (SGX Nifty) suggested that the domestic indices would begin cautiously.

As China’s official index of factory activity decreased in July, Asian markets were down.

At home, the broad NSE Nifty advanced 85 points or 0.50 percent to trade at 17,243, while the 30-share BSE Sensex rose 226 points or 0.39 percent to 57,796 in early session.

Mid- and small-capitalization shares performed well, with the Nifty Midcap 100 increasing by 0.27 and 0.32 percent, respectively.

The National Stock Exchange’s 15 sector gauges, which were compiled, were trading up on nine of them. The NSE platform was outperformed by the sub-indices Nifty Auto and Nifty Metal, which increased by as high as 1.34 and 0.84 percent, respectively.

In terms of individual stocks, M&M was the highest Nifty gainer, rising 5.91% to ₹1,229.80. The gainers included Cipla, Maruti, Tata Motors, and PowerGrid.

1,833 equities on the BSE were rising while 787 were falling, indicating a healthy market breadth overall.

M&M Maruti, PowerGrid, Reliance Industries, UltraTech Cement, Bajaj Finance, Wipro, Tata Steel, Dr. Reddy’s, Asian Paints, Bharti Airtel, and HCL Technologies were among the top gainers on the 30-share BSE index.

Additionally, shares of Life Insurance Corporation of India (LIC), the largest domestic financial investor and insurer in the nation, increased 0.37 percent to trade at ₹680.35.

Sun Pharma, IndusInd Bank, Hindustan Unilever, Axis Bank, Titan, and TCS, on the other hand, were all trading at a loss.

On Friday, the Sensex increased by 712 points, or 1.25 percent, to close at 57,570, while the Nifty increased by 229 points, or 1.35 percent, to end the day at 17,158.

India to accept 1-Dose Sputnik Light Trial Data from Russia

Faara Nadeem — Thu, 01 Jul 2021 15:24:12 +0000

Russian Phase 3 trial data for the single-dose Sputnik Light COVID-19 shot in India can be submitted said a government expert panel. Hours after reports came out that stated that they had been denied approval for the trial in India, Dr. Reddy’s, the vaccine’s India partner reported on Thursday.

The makers of the first shot of the Russian-made Sputnik V vaccine, Sputnik Light claim that it demonstrated the efficacy of 79.4 percent.

The company said in a statement, “On Wednesday 30th June, the SEC (Subject Expert Committee) deliberated on the submission for Marketing Authorisation of Sputnik Light in India from Dr. Reddy’s. The company presented to the SEC, interim safety and efficacy data from the Phase I / II clinical trial of Sputnik Light in Russia, along with a clinical trial protocol for a Phase III trial of Sputnik Light in India. In view of the fact that (1) Sputnik Light is the first dose component of Sputnik V, and Dr. Reddy’s has already generated safety and immunogenicity data on the first dose component in India through its clinical trial and; (2) a phase III efficacy trial is currently underway in Russian on Sputnik Light, the SEC recommended that Dr. Reddy’s should submit safety, immunogenicity and efficacy data from the phase III clinical trial of Sputnik V in Russia to the SEC for its consideration of Marketing Authorisation of Sputnik Light in India.”

Dr. Reddy’s also said that the SEC also observed that Dr. Reddy’s in India on the first dose component of Sputnik V (in other words, Sputnik Light), there was no need for a separate Phase III trial of Sputnik Light in India keeping the safety and immunogenicity data already generated in view.

In May, Dr. Reddy had told NDTV that the Russian vaccines can become the first single-dose vaccine to be used if approved.

Delay in commercial launch of Sputnik V, says Dr Reddy

Aayushi Singh — Tue, 29 Jun 2021 09:44:49 +0000

There has been a slight postponement in the timeline of the commercial launch of Sputnik V Coronavirus vaccine due to dependency on imported consignments and quality testing in India, said Dr Reddy. Dr Reddy did not specify the commercial launch date of the Russian Vaccine.

A spokesperson from the company on June 29 said that the cold storage and other logistical arrangements were being executed in line with their commercialisation plan and were on track with no issues.

The Russia made Sputnik Vaccine was to be manufactured in India by Dr Reddy and a few other pharmaceutical firms.

The Union Ministry of Health and Family Welfare had been looking into delayed supply’s of Covaxin doses and had discussed the issue with the manufacturer, Bharat Biotech.

In India, three million doses of Sputnik had arrived and the consignment the second dose was likely to land by the end of June. The company had said that it was updating government authorities, media and members of the public on a daily basis.

As per Sputnik’s V Vaccines agreement with Russian sovereign fund RDIF, Dr Reddy is the brand custodian of the vaccine in India and has sole distribution rights for the first 250 million doses in India.

Including GST, Sputnik V had been priced at Rs 995 per dose. Russia would import the first 50 million jabs ensuring a speedier rollout before the Indian pharmaceuticals company’s start producing the Sputnik V vaccines.

The company said that they had partnered with the major hospitals all over the country and several partners had successfully administered Sputnik V as a part of the pilot phase and including the limited stock pilot roll-outs to the public in various cities.

Dr Reddy initiated the limited pilot soft launch of the Sputnik V vaccine in India in Hyderabad on May 14, which has successfully scaled up to Delhi, Kolkata, Mumbai, Lucknow, Jaipur, Ranchi, Coimbatore, Nashik, Nagpur, Pune, Chandigarh, Raipur, Kochi, Kolhapur, Baddi, Vijayawada, Chennai, Miryalaguda, Patna, Bengaluru and Vizag.

The company said that it aimed to reach 28 cities by the end of the final pilot phase. The company added that the pilot phase had allowed them to test their cold storage arrangements of -18 degree Celsius temperature in these cities, CoWIN integration, track and trace and various other logistical arrangements had been made before their commercial launch.

Dr Reddy’s Labs seek emergency-use approval for Sputnik-V COVID-19 vaccine

Arnav Dogra — Fri, 19 Feb 2021 13:06:29 +0000

Indian Pharmaceutical giant, Dr Reddy’s Laboratories, is now seeking emergency-use approval for Russia’s Sputnik-V vaccine in the country.

The Sputnik-V vaccine is Dr Reddy’s joint operation with the Russian Direct Investment Fund (RDIF), which has been working for months now to put the vaccine into use. The vaccine, in late-stage trials in Russia, has proven to be 91.6% effective against the COVID-19 virus.

The safety profile of the vaccine, which has been developed by Moscow’s Gamaleya Institute, from a mid-stage study and the interim data from a late-stage trial will be presented by the drug maker by February 21, according to the pharmaceutical.

Sputnik V has shown commercial success as it as already been authorized and registered in nearly 30 countries. Once granted approval, it will be the vaccine with the highest efficacy percentage among all the vaccines currently underuse in India.

The Oxford-developed vaccine, which is currently being manufactured by the Pune-based Serum Institute of India, has an efficacy rate of only 60% which is far behind the Sputnik-V vaccine whereas the vaccine developed by Hyderabad-based Bharat Biotech has not yet released any data on the efficacy and safety of its vaccine branded ‘Covaxin’.

Dr Reddy’s Laboratories Q3 report: Net profit of Rs 20 crore

Sanah Shah — Fri, 29 Jan 2021 07:32:35 +0000

Dr Reddy’s Laboratories on 29th January 2021 reported consolidated net profit at Rs 20 crore for the quarter ended December 2020, in comparison to a loss of Rs 569.7 crore in the year-ago period.

The company said the Q3FY21 PAT had improved mainly due to the non-recognition of deferred tax assets on impairment.

Revenue for the quarter stood at Rs 4,930 crore which had increased by 12% YoY and 1% QoQ. The gross margin was 53.8% against 54.1% YoY and 53.9% QoQ. Selling, general and administrative (SG&A) expenses advanced 14% YoY and 10% QoQ to Rs 1,439 crore. Research and development expenses were Rs 411 crore for the quarter.

Earnings before interest, taxes, depreciation and amortization (EBITDA) was at Rs 1,185 crore and EBITDA margin stood 24% for Q3FY21.

The company’s Co-chairman & MD, G V Prasad stated, “We continued with our growth momentum while maintaining EBITDA margins. The profits were impacted due to trigger based impairment charge taken on a few acquired products including Nuvaring.”

“We are progressing well on phase 3 clinical trials for Sputnik V vaccine in India. We continue to focus on enhancing our product offerings to our patients to serve them better,” he added.

In the geographical segments, Europe and India were in the lead, rising 34% and 26% YoY, respectively.

North America observed growth of 9% YoY. On the other hand, emerging markets advanced by 5% YoY during the December quarter.

Proprietary products and several other segments rose by 53% YoY but pharmaceutical services and active ingredients (PSAI) segment improved by the only % YoY.

Revenue from global generics saw YoY growth of 13% and sequential growth of 2%, fundamentally driven by new product inaugurations and integration of the acquired portfolio from Wockhardt in India.

Dr Reddy’s relaunches over-the-counter Famotidine Tablets in the US market

Anu Jain — Tue, 20 Oct 2020 07:51:53 +0000

Dr Reddy’s has relaunched over-the-counter (OTC) Famotidine Tablets in the US market. It prevents and relieves heartburn as well as decreases stomach acid production brought on by eating or drinking certain food and beverages. The drug starts working within an hour.

Over-the-counter drugs are those medicines which are directly sold to the consumers without a prescription from a healthcare professional.

In October 2017, Dr Reddy’s had recalled 569,000 store-brand famotidine tablets in the U.S. due to failed tests for impurities and degradation and it was its second recall of the same medication since July 2016.

The medicines were sold at CVS pharmacies classifying as Class III recall. According to the United States, Food and Drug Administration recall policies, Class III recall means that the suspect drugs aren’t likely to cause injury to humans.

In July 2016, Dr Reddy’s pulled more than 84,000 famotidine tablets and also produced for CVS. In both cases, the company was found an out-of-specification result during routine stability testing.

Remdesivir, COVID-19 drug launched by Dr. Redddy’s Labortaories

Anjana Krishna — Wed, 09 Sep 2020 06:33:04 +0000

Dr. Redyy’s Laboratories announced the launch of the antiviral drug Remdesivir, under the brand name Redyx in India for the treatment of COVID-19 patients. The drug is approved by the Drug Controller General of India (DCGI) for COVID-19 patients who are hospitalized and in critical condition.

The launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India. The drug will be available in strength of 100 mg vial,

” The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”. Chief Executive Officer of Branded Markets (India and Emerging Markets), Dr Reddys Laboratories, M V Ramana said. He also added that they will continue their efforts to develop products that address other significant unmet needs of patients.